Abstract
Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Infectious Disorders - Drug Targets
Title:Tuberculosis Vaccines: Hopes and Hurdles
Volume: 13 Issue: 5
Author(s): Mohamed J. Ahsan, Shiv K. Garg, Bharat Vashistha and Piush Sharma
Affiliation:
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Abstract: Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Export Options
About this article
Cite this article as:
Ahsan J. Mohamed, Garg K. Shiv, Vashistha Bharat and Sharma Piush, Tuberculosis Vaccines: Hopes and Hurdles, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526513666131201125513
DOI https://dx.doi.org/10.2174/1871526513666131201125513 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Design, Synthesis and Biological Evaluation of Novel Tetrahydroquinoline Based Propanehydrazides as Antitubercular Agents
Letters in Drug Design & Discovery Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry A Review of the English and Russian Language Literature on the Osteoarticular Manifestations of Brucellosis Infection
Current Rheumatology Reviews S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Evaluation of Brazilian Biotechnology Patent Activity from 1975 to 2010
Recent Patents on DNA & Gene Sequences An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis
Current Topics in Medicinal Chemistry Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Oxazolidinone Antibacterials and Our Experience
Anti-Infective Agents in Medicinal Chemistry Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori
Current Drug Therapy Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review
Current Pharmaceutical Design Editorial (Hot Topic: Emerging Therapeutic Targets in Inflammation and Allergy Drug Discovery from Patent Perspective)
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis, Characterizations and Microbial Studies of Novel Mannich Products Using Multicomponent Reactions
Current Bioactive Compounds Deep Transfer Learning for COVID-19 Prediction: Case Study for Limited Data Problems
Current Medical Imaging Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges
Current Topics in Medicinal Chemistry The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry